Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.54 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6101342 | 0.85 | HTR3A (0.59) | BCAT1HTR3ACHRNA7 | |
| SCHEMBL6100330 | 0.82 | SSTR3 (0.47) | — | |
| Hydrochloric Acid SCHEMBL7126791 | 0.81 | SSTR3 (0.46) | — | |
| SCHEMBL7232870 | 0.81 | HPGDS (0.38) | HPGDSCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6101178 | 0.81 | HPGDS (0.52) | HPGDSBCAT1CXCR4MGAMABCB1 | |
| SCHEMBL6100127 | 0.80 | HPGDS (0.51) | HPGDSBCAT1CXCR4MGAMABCB1 | |
| SCHEMBL5917815 | 0.79 | CHRNA7 (0.48) | HTR3ACHRNB2CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL5231652 | 0.78 | CHRNA7 (0.47) | HTR3ACHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6832879 | 0.75 | HPGDS (0.57) | HPGDSBCAT1CXCR4MGAMABCB1 | |
| SCHEMBL5258735 | 0.75 | HPGDS (0.57) | HPGDSBCAT1CXCR4MGAMABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | HPGDS 1600/4885BCAT1 1476/4885CXCR4 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.